P519 Analysis of the effectiveness and safety of switching from originator to biosimilar adalimumab in patients with Inflammatory Bowel Disease
Authors: Casanova M J , Chaparro M , Nantes Ó , Varela P , Vela-González M , Montserrat R , Sierra O G , Riestra S , Barreiro-de Acosta M , Martín-Rodríguez M M , Gargallo-Puyuelo C J , Reygosa C , Muñoz R , García de la Filia-Molina I , Núñez-Ortiz A , Kolle L , Calafat M , Huguet J M , Iglesias-Flores E , Martínez-Pérez T J , Bosch O , Duque-Alcorta J M , Frago-Larramona S , Sánchez-Azofra M , Van Domselaar M , González-Cosano V M , Bujanda L , Rubio S , Mancebo A , Castro B , García-López S , de Francisco R , Nieto L , Laredo V , Gutiérrez A , Mesonero F , Leo-Carnerero E , Cañete F , Ruiz L , Gisbert J P 
Published: January 2022

Background

Aims: 1) to compare persistence on adalimumab treatment over time in inflammatory bowel disease (IBD) patients who maintained adalimumab reference [non-switch cohort (NC)] vs. those who switched from adalimumab reference to adalimumab biosimilar [switch cohort (SC)]; 2) to compare loss of effectiveness of adalimumab treatment in the NC vs. SC; 3) to identify factors associated with discontinuation of adalimumab therapy; 4) to identify the factors associated with relapse in both cohorts; and 5) to evaluate the safety of both strategies.

Methods

Retrospective, observational, multicentre study. Patients under adalimumab reference who were in clinical remission at standard dose of adalimumab reference, and in whom adalimumab was the first anti-TNF administered, were included. Clinical remission was defined as a Harvey-Bradshaw index ≤4 points in Crohn’s disease, a partial Mayo score ≤2 in ulcerative colitis, and the absence of fistula drainage despite gentle finger compression in perianal disease. The follow-up time was at least 6 months since start of study observation period. The Kaplan-Meier method with log-rank test was used to evaluate the cumulative incidence of treatment discontinuation. Cox regression model was used to investigate factors potentially associated with therapy discontinuation.

Results

A total of 505 patients were included (45% women, 87% Crohn’s disease): 229 in the SC and 276 in the NC. The median follow-up was 12 months in the SC and 23 months in the NC (p&lt;0.01). The incidence rate of adalimumab discontinuation was 10% [95% confidence interval (95%CI)=6–14%], and 7% (95%CI=5–10%) per patient-year in the SC and in the NC, respectively (p=0.035). The probability of maintaining adalimumab was 92% at 12 months and 77% at 24 months in the SC, and 97% at 12 months and 86% at 24 months in the NC. In the multivariable analysis, the switch to adalimumab biosimilar, adjusted for the level of C-reactive protein at baseline, was not associated with therapy discontinuation. 18% of the patients relapsed in the SC vs. 21% in the NC. The incidence of relapse was 17% (95%CI=13–23%) in the SC, and 12% (95%CI=10–16%) per patient-year in the NC (p=0.04). The cumulative incidence of relapse was 11% at 12 months and 38% at 24 months in the SC, and 11% at 12 months and 22% at 24 months in the NC. In the multivariable analysis, the switch to adalimumab biosimilar (adjusted by type of IBD) was associated with a higher risk of relapse (HR=1.5, 95%CI=1.008–2.36). 4% of the patients had adverse events in the SC vs. 8% in the NC (p&gt;0.05).

Conclusion

The incidence rate of relapse was slightly higher in the SC; however, this fact had no impact on persistence on the drug. Switching from adalimumab reference to adalimumab biosimilar was safe.